Medical/Pharmaceuticals News & Press Release Distribution

Medical/Pharmaceuticals

APAC
Global

Esaote unveils its new brand identity at 2024 Worldwide Sales & Marketing Meeting, Florence

A new logo and the new "Health with Care" payoff, to convey innovation and technology with empathy GENOA, Italy, Jan. 25, 2024 /PRNewswire/ -- Esaote Group, a leading Italian innovator in medical imaging, todayunveiled its new brand identity at the 2024 Worldwide Sales & Marketing Meeting inFlor...

2024-01-25 21:00 2506

First International Shipment of HANSIZHUANG

SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- On January 25, a truck carrying HANSIZHUANG Zerpidio® (anti-PD-1 monoclonal antibody, Chinese trade name: HANSIZHUANG) slowly left Henlius' Songjiang First Plant. These products, bearing Henlius' mission of "benefiting patients worldwide with high-quality ...

2024-01-25 20:45 4438

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

* Glenmark will be responsible for further developing, registering, and commercializing Envafolimab inIndia, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. * Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additio...

2024-01-25 18:38 1947

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

2024-01-25 18:00 1899

Asieris will Present For the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU

SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the interi...

2024-01-25 16:56 1628

Alphamab Oncology and 3DMedicines Entered into a Licensing Agreement with Glenmark for KN035

SUZHOU, China, Jan. 25, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and 3DMedicines (stock code: 1244.HK) ("Licensors") announced that we entered into a license agreement with Glenmark Specialty S.A. (GSSA), a subsidiary of Glenmark Pharmaceuticals Ltd. (BSE: 532296，NSE: GLENMARK...

2024-01-25 10:40 1955

PS128 Successfully Targets Behavioral and Emotional Challenges in Autism Spectrum Disorder (ASD): Completion of Pivotal Clinical Trial on Preschool Children with ASD

SAN DIEGO, Jan. 25, 2024 /PRNewswire/ -- A recent study published in the Research in Autism Spectrum Disorders unveils groundbreaking solutions for neurodevelopmental disorders. This is the first double-blinded, randomized, placebo-controlledtrial

2024-01-25 10:00 2193

PS128 Successfully Targets Behavioral and Emotional Challenges in Autism Spectrum Disorder (ASD): Completion of Pivotal Clinical Trial on Preschool Children with ASD

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

- WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by producing afucosylated antibodies with the ability to increase antibody-dependent cell-mediated cytotoxicity (ADCC), providing diverse bioprocessing solutions for global clients - WuXiaADCC PLU...

2024-01-25 08:30 1726

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

icotec ag raises $30m in growth financing from MVM Partners

ALTSTAETTEN, Switzerland and EAST HARTFORD, Conn., Jan. 24, 2024 /PRNewswire/ -- icotec ag, the leading company in the field of innovative spinal tumor implants is pleased to announce a significant milestone in its growth journey by establishing a strategic partnership with MVM Partners ("MVM"), ...

2024-01-25 01:45 1821

FDA purchases digiM I2S software for the assessment of product quality attributes

Reviewers and regulatory researchers to use AI image analytics for process-quality correlation WOBURN, Mass., Jan. 24, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration has placed a purchase order (75F40123P00369) committing to an annual subscription of digiM I2S, a fully integrated ima...

2024-01-24 23:37 1658

Wellysis Goes Global with ECG Monitor 'S-Patch', Enters US and Indian Markets

SEOUL, South Korea, Jan. 24, 2024 /PRNewswire/ -- Digital healthcare innovator Wellysis is making waves in the global market with its revolutionary electrocardiogram (ECG) monitoring solution, 'S-Patch,' securing strategic partnerships and distribution deals to propel its entry into the lucrative...

2024-01-24 22:00 1810

Wellysis Goes Global with ECG Monitor 'S-Patch', Enters US and Indian Markets

WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit

CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements,Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit inBerlin, Germany. Renowned for her pivotal role in mRNA research, Dr.Xiangrong Song, co-founder and CEO o...

2024-01-24 21:32 1593

WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit

Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy

The study confirms that Xanamem is a brain-penetrant inhibitor of the tissue cortisol synthesis enzyme, 11β-HSD1, with high levels of target occupancy at doses as low as 5 mg SYDNEY, Jan. 24, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that its human Positron Emission Tom...

2024-01-24 21:30 1661

Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI

* Results showed partial response being confirmed in 7 out of 42 patients * Partial response was observed in 3 out of 8 patients who were previously treated by immunotherapy SEOUL, South Korea, Jan. 24, 2024 /PRNewswire/ -- Genome & Company (KOSDAQ: 314130), a clinical stage biotech leading in...

2024-01-24 21:00 1642

Seegene Announces Collaboration with Microsoft to Realize 'a World Free from All Diseases'

* Strategic collaboration to open a new chapter in the field of molecular diagnostics that aspires to 'a world free from all diseases and future pandemics' * Digitally enhance Seegene's automated diagnostic reagent development system with the integration of Microsoft Azure AI solutions * A ...

2024-01-24 20:00 2657

Seegene Announces Collaboration with Microsoft to Realize 'a World Free from All Diseases'

SHL Medical partners with SteriPack Group to set up final assembly service

ZUG, Switzerland, Jan. 24, 2024 /PRNewswire/ -- SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic par...

2024-01-24 18:00 1991

SHL Medical partners with SteriPack Group to set up final assembly service

Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors

Study published in NAR Cancer, a leading peer-reviewed journal in the field of nucleic acid therapeutics HONG KONG, Germantown, Md. and SUZHOU, China, Jan. 24, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a l...

2024-01-24 17:49 1918

Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

HANGZHOU and SHAOXING, China, Jan. 24, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces dosing of the first patient in Phase III clinical trial of ASC40 (Denifanstat) for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University. This P...

2024-01-24 16:50 2451

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

EPALINGES, Switzerland and PARIS, Jan. 24, 2024 /PRNewswire/ -- Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a firs...

2024-01-24 15:00 1461

Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 23, 2024 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that the Company has been granted the clearance of Investigational New Drug (IND) from the Food and Drug Administration (FDA) ofthe United States to init...

2024-01-24 12:40 1663

1 ... 101 102 103104105 106 107 ... 611

Week's Top Stories

Most Reposted

QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology

[Picked up by 303 media titles]

2024-11-26 18:49

ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability

[Picked up by 296 media titles]

2024-11-28 17:24